Led by experienced scientific pioneers and capital markets professionals dedicated to advancing next-generation metabolic therapeutics and driving shareholder value.
Our team combines breakthrough peptide innovation expertise with advanced developmental agility and capital markets experience to deliver outsized returns.
Chief Executive Officer, President & Director
Charles MaLette was previously an Investment Advisor for more than 35 years with Canaccord Genuity Corp., with many years investing, financing, analyzing and reviewing public companies in various industries. Graduated from the University of Calgary with a degree in Economics, and completed a teaching degree from the University of British Columbia.
Chief Financial Officer & Director
James Bordian is a retired Chartered Accountant and Certified Internal Auditor with over 40 years experience. He has held senior management positions with US Plywood, Dillingham Corporation, Air Canada, and BC Hydro. Extensive experience in income tax planning, budgeting, financial statement presentations and business valuations.
Inventor and Advisor
Dr. Robert Doyle is a medicinal chemist focused on drug development for obesity and type 2 diabetes. Specialized in peptide and protein design, recombinant expression, bioconjugate chemistry, and drug delivery. He joined Syracuse University in 2005, was named the Laura J. and L. Douglas Meredith Professor in 2016 and Dean’s Professor of Chemistry in 2022. Holds appointments as Associate Professor of Medicine at SUNY.
Chief Scientific Officer
Dr. Nihar Pandey is a biochemist and clinical researcher with 25+ years of experience in drug discovery, development, and regulatory strategy. Developed 7 IP-protected drug formulations, holds five active patents, and published 35+ peer-reviewed papers. Previous roles at University of Ottawa Heart Institute, Liponex Inc., and Health Canada in regulatory toxicology.
Obesity Expert and Advisor
Dr. Billing is a Mayo-trained metabolic bariatric surgeon, entrepreneur and clinical investigator. He serves as a courtesy medical staff member at Swedish First Hill and holds leadership roles, including Medical Director at Transform SurgiCenter. Robust publication record on surgical treatments and bariatric procedures. Named a Top Doctor by Castle Connolly in 2023.
Corporate Development
Tara Asfour is a capital markets executive with over 12 years of experience in investor relations, fundraising, and corporate communications across resource and technology sectors. She has led more than US$550 million in fundraising and strategic initiatives. Ms. Asfour holds an MBA from Herzing University and executive certificates from Yale and HBS.